Roche's Alzheimer's Blood Test Receives U.S. FDA Approval
Nashnova编辑部
Roche's pTau217 blood test has won FDA approval, becoming the first single-biomarker blood test that can both rule in and rule out amyloid pathology linked to Alzheimer's — potentially replacing costly PET scans and invasive spinal taps in early screening.
What can this test actually do?
Roche's Elecsys pTau217 — a plasma test measuring phosphorylated Tau 217 protein — is now FDA-approved to help identify amyloid pathology in people aged 55 and older with cognitive decline.
The key breakthrough: it is the first and only FDA-approved single-biomarker blood test that can both "rule out" and "rule in" amyloid pathology using one validated set of cutoff values.
In plain terms = detecting amyloid plaques in the brain used to require either a PET scan (expensive) or a lumbar puncture (invasive). Now a single blood draw can give a preliminary answer — in both directions.
Who is behind it?
The test was co-developed by Roche and Eli Lilly — both major players in Alzheimer's therapeutics.
This means → diagnostics and treatment are forming a closed loop. Lilly already markets anti-amyloid antibody drugs; now it has helped build the screening tool that feeds patients toward those treatments.
Labcorp, one of the largest U.S. laboratory networks, plans to roll out the test nationwide over the coming months.
What does this mean for patients and the market?
The test is cleared for use in both primary-care and specialist settings. This means → a community physician can order it directly, without referring every patient to a hospital neurology department.
In plain terms = the "front door" for Alzheimer's screening widens from a handful of specialist centers to ordinary clinics nationwide.
The next milestone the market is watching: Labcorp's actual rollout pace and test pricing — these will determine how quickly the technology reaches patients at scale.
Content is for reference only, not financial advice.